High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation
Luyuan Li, Lily Hashemi, Josiane Eid, Wensi Tao, Leticia Campoverde, Amy Yu, Ammad Ahmad Farooqi, Hassan Al-Ali, Gina D’Amato, Francis Hornicek, Zhenfeng Duan, Ines Lohse, Jonathan Trent, Michela Rossi · 2024
Read High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation by Luyuan Li, Lily Hashemi, Josiane Eid, Wensi Tao, Leticia Campoverde, Amy Yu, Ammad Ahmad Farooqi, Hassan Al-Ali, Gina D’Amato, Francis Hornicek, Zhenfeng Duan, Ines Lohse, Jonathan Trent, Michela Rossi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11641203.txt.
Description
Luyuan Li leads a team that screens drugs on a rare bone tumor. Their study from twenty twenty-four deals with chondrosarcoma, a cartilage tumor. Such tumors tend to shrug off chemo and radiation.
The team tested a panel of cancer drugs on tumor cell lines. Some lines had a gene fault and some had it removed. Top drugs worked well no matter the fault status. That matters, since fault drugs alone have shown weak results. A few top drugs were picked for more deep tests. Mix care is the goal of this search.
Catalog record
| CREATOR | Luyuan Li, Lily Hashemi, Josiane Eid, Wensi Tao, Leticia Campoverde, Amy Yu, Ammad Ahmad Farooqi, Hassan Al-Ali, Gina D’Amato, Francis Hornicek, Zhenfeng Duan, Ines Lohse, Jonathan Trent, Michela Rossi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |